Table 4.
(a) | ||||||||||||
Patient | Sex | Age (years) | Number of Comorbidities | ESCPM Species | ESBL | Suspected Site Associated witd BSI | Healthcare-Associated Infection | qPitt Score for Severity | Initial Empirical Therapy according to AST | Clinical Stability after 48 h | Delay Until Reassessment of Therapy in Case of Switch (days) | In-Hospital Death |
1 | M | 65 | 2 | Enterobacter cloacae | Yes | Urinary | No | 0 | Effective | Yes | No change | No |
2 | M | 69 | 2 | Enterobacter cloacae | No | Gastrointestinal | No | 0 | Ineffective | Yes | 5 | No |
3 | F | 77 | 3 | Klebsiella aerogenes | No | Vascular | No | 0 | Ineffective | No | 3 | No |
4 | M | 72 | 2 | Enterobacter cloacae | No | Pulmonary | Yes | 2 | Ineffective | Yes | No change | Yes |
5 | M | 88 | 4 | Enterobacter cloacae | Yes | Urinary | No | 0 | Ineffective | No | 5 | No |
6 | F | 69 | 1 | Enterobacter cloacae | No | Gastrointestinal | No | 1 | Ineffective | No | No change | Yes |
7 | M | 89 | 2 | Enterobacter cloacae | Yes | Vascular | Yes | 0 | Effective | Yes | 2 | No |
8 | F | 70 | 1 | Enterobacter cloacae | No | Gastrointestinal | No | 2 | Effective | Yes | No change | No |
9 | M | 58 | 1 | Enterobacter cloacae | No | Gastrointestinal | No | 0 | Ineffective | Yes | 1 | No |
10 | M | 56 | 1 | Providencia stuartii | No | Urinary | No | 2 | Ineffective | No | 3 | No |
11 | F | 85 | 2 | Morganella morgnaii | No | Urinary | No | 0 | Effective | Yes | No change | No |
12 | F | 85 | 3 | Pantoea agglomerans | No | Vascular | No | 0 | Effective | No | 2 | No |
13 | M | 91 | 1 | Morganella morgnaii | No | Urinary | No | 1 | Effective | No | 1 | Yes |
14 | M | 81 | 3 | Serratia marcescens | No | Gastrointestinal | No | 0 | Ineffective | No | 3 | No |
15 | M | 69 | 2 | Serratia marcescens | No | Skin and soft tissues | Yes | 0 | Effective | Yes | No change | No |
16 | M | 77 | 4 | Serratia marcescens | No | Gastrointestinal | Yes | 0 | Ineffective | No | No change | No |
17 | F | 79 | 3 | Serratia marcescens | No | NA | No | 1 | Ineffective | No | No change | Yes |
18 | M | 54 | 2 | Serratia marcescens | No | Vascular | No | 0 | Effective | No | 10 | Yes |
(b) | ||||||||||||
Patient | Sex | Age | Number of Comorbidities | Enterobacterales Species | Suspected Site Associated with BSI | Healthcare-Associated Infection | qPitt Score for Severity | Initial Empirical Therapy | Clinical Stability after 48 h | Delay until Reassessment of Therapy in Case of Switch (days) | In-Hospital Death | |
1 | M | 65 | 2 | Enterobacter cloacae | Urinary | No | 0 | Effective | Yes | No change | No | |
2 | M | 83 | 3 | Escherichia coli | Pulmonary | No | 2 | Ineffective | No | 2 | Yes | |
3 | M | 88 | 4 | Enterobacter cloacae | Urinary | No | 0 | Ineffective | No | 5 | No | |
4 | M | 89 | 2 | Enterobacter cloacae | Vascular | Yes | 0 | Effective | Yes | 2 | No | |
5 | F | 63 | 2 | Escherichia coli | Urinary | No | 0 | Ineffective | No | 2 | No | |
6 | F | 83 | 2 | Klebsiella pneumoniae | Urinary | Yes | 1 | Effective | Yes | No change | No | |
7 | F | 88 | 3 | Escherichia coli | Gastrointestinal | No | 2 | Ineffective | Yes | 4 | No | |
8 | F | 78 | 2 | Escherichia coli | Urinary | No | 0 | Ineffective | Yes | 5 | No |
ESCPM: Enterobacter sp., Serratia marcescens, Citrobacter freundii, Providencia sp., Morganella morganii; ESBL: extended-spectrum beta-lactamase; BSI: bloodstream infection; AST: antibiotic sensitivity testing.